Blau Farmacêutica Q3 2026 net profit falls 35% year over year to BRL 68.98 million

PUBT · 5d ago
Blau Farmacêutica Q3 2026 net profit falls 35% year over year to BRL 68.98 million
  • Blau Farmacêutica’s third-quarter 2026 net income fell 35% year over year to BRL 68.98 million.
  • Net revenue rose 7% year over year to BRL 506.34 million, led by hospital-segment growth.
  • The financial result swung to a BRL 20.45 million loss; the year-earlier quarter benefited from the Prothya divestment.
  • Four medicines secured regulatory approval during the quarter: two in Brazil and two elsewhere in Latin America.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blau Farmaceutica SA published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.